Johnson Johnson
Latest news, explainers and analysis on Johnson Johnson. Tracking 3 stories on Arth Vani.
Connected in the graph
Latest on Johnson Johnson
J&J's $5.5 Billion Talc Settlement: A Clear Path or Lingering Legal Cloud?
Johnson & Johnson (J&J) has proposed a $5.5 billion (approximately ₹45,800 crore) settlement to resolve a significant portion of lawsuits alleging its talc products caused cancer. This move prompts investors to question whether the substantial offer signals an end to the company's prolonged legal challenges or if significant risks still loom.
Jim Cramer: J&J Market Influencing Wall Street Activity Amid Settlement Talks
Prominent US financial commentator Jim Cramer has characterized recent trading on Wall Street as a 'J&J market,' indicating that Johnson & Johnson is a significant driver of current market sentiment. This positive outlook is reportedly linked to the global healthcare giant's ongoing talc settlement discussions and other fundamental strengths.
Johnson & Johnson Beats Q2 2026 Earnings Estimates on Strong Medicine Sales
Global healthcare giant Johnson & Johnson reported stronger-than-expected earnings for the second quarter of 2026, driven by its pharmaceutical division. The company saw robust demand for its core medicines, offsetting challenges in other segments.
Some listings may be sponsored and Arth Vani may earn a referral fee. All information is for educational purposes only — verify terms and suitability with the provider before acting. Not financial advice.